Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2387-2394

  Knox, A ^a   Langan, J ^b   Martinot, J B ^c   Gruss, C ^d   Hafner D ^d  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Baillieston Health Centre   (United Kingdom)

^c Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^d ALTANA PHARMA AG   (Germany)

Author keywords

Asthma control; Ciclesonide; Fluticasone propionate; Once daily; Step down; Treatment guidelines

Indexed keywords

CICLESONIDE; FLUTICASONE PROPIONATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEMOGRAPHY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHONIA; DYSPNEA; FEMALE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MUMPS; ORCHITIS; PLEURISY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; THRUSH; TRACHEITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNENEDIONES; TREATMENT OUTCOME;

EID: 35648968157     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X226203     Document Type: Article

References (35)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2006. Available at: www.ginasthma.org [accessed May 2007]
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002;110:S141-S219
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157:S1-S53
4. Halterman JS, Aligne CA, Auinger P, et al. Inadequate therapy for asthma among children in the United States. Pediatrics 2000;105:272-6
5. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-92
6. Blaiss MS, Kaliner MA, Valovirta EJ, et al. GAPP survey: patient education and patient-physician communications - global findings. Oral presentation at the American College of Allergy, Asthma and Immunology Annual Meeting 2005. Available at: www.gappsurvey.org/ppt/GAPP_Survey_Core_Slides.ppt [accessed May 2007]
7. Guest JF, Davie AM, Ruiz FJ, et al. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005;14:88-98
8. British Thoracic Society. British guideline on the management of asthma. SIGN guideline No. 63. Revised November 2005. Available at: www.sign.ac.uk/pdf/ sign63.pdf [accessed May 2007]
9. Bateman ED. Measuring asthma control. Curr Opin Allergy Clin Immunol 2001;1:211-6
10. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65
11. Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001;17:589-95
12. Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2007 May 21 [epub ahead of print]
13. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006;19:404-12
14. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328-36
15. Pedersen S, Garcia Garcia ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 μg/day and fluticasone propionate 176 μg/day in children with asthma. Pediatr Pulmonol 2006;41:954-61
16. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94:465-72
17. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005;128:1104-14
18. Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007;101:1677-86
19. Busse WW, Kaliner M, Bernstein D, et al. The novel inhaled corticosteroid ciclesonide is efficacious and has a favorable safety profile in adults and adolescents with severe persistent asthma. J Allergy Clin Immunol 2005;115:S213
20. Magnussen H, Hofman J, Novakova B, et al. Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients. Eur Respir J 2005;25(Suppl. 49):255s
21. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005;127:851-60
22. Engelstätter R, Escher A, Haefner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 2005;26(Suppl. 49):255s
23. Humbert M. Ciclesonide: a novel inhaled corticosteroid. Expert Opin Investig Drugs 2004;13:1349-60
24. Christie P. Ciclesonide: a novel inhaled corticosteroid for asthma. Drugs Today (Barc) 2004;40:569-76
25. Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother 2006;7:2107-17
26. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. [This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986]. Am Rev Respir Dis 1987;136:225-44
27. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. New Engl J Med 1994;331:700-5
28. Juniper EF, Kline PA, Vanzieleghem MA, et al. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991;87:483-9
29. Stallberg B, Olsson P, Jorgensen LA, et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003;57:656-61
30. Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 2002;109:929-35
31. Foresi A, Mastropasqua B, Chetta A, et al. Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma. Chest 2005;127:117-24
32. Giannini D, Di Franco A, Tonelli M, et al. Fifty μg b.i.d. of inhaled fluticasone propionate (FP) are effective in stable asthmatics previously treated with a higher dose of FP. Respir Med 2003;97:463-7
33. Purucker ME, Rosebraugh CJ, Zhou F, et al. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003;124:1584-93
34. Boulet LP, Cowie RL, Negro RD, et al. Comparison of once-with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Can Respir J 2000;7:239-47
35. Black PN, Lawrence BJ, Goh KH, et al. Differences in the potencies of inhaled steroids are not reflected in the doses prescribed in primary care in New Zealand. Eur J Clin Pharmacol 2000;56:431-5